← FDA DRUG APPROVALS

FDA NDA · NDA019860

IMODIUM A-D

Sponsor: KENVUE BRANDS

APPLICATION
NDA019860
TYPE
NDA
ORIGINAL APPROVAL
1989-11-22
LATEST ACTION
2019-03-07
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Over-the-counter

Products

IMODIUM A-D · ReferenceOver-the-counter
LOPERAMIDE HYDROCHLORIDE 2MG · TABLET · ORAL

Approval history

2019-03-07Labeling · Supplement 33 · standardLetterAP
2017-04-12Labeling · Supplement 32 · standardLabelAP
2013-02-21Manufacturing (CMC) · Supplement 31 · standardAP
2012-05-03Labeling · Supplement 29 · standardLetterAP
2004-06-16Labeling · Supplement 20 · standardReviewAP
2001-04-05Labeling · Supplement 18 · standardLetterAP
2000-09-26Manufacturing (CMC) · Supplement 19 · standardAP
2000-05-11Manufacturing (CMC) · Supplement 17 · standardAP
1999-11-29Manufacturing (CMC) · Supplement 16 · standardAP
1999-11-24Manufacturing (CMC) · Supplement 15 · standardAP
1998-09-04Manufacturing (CMC) · Supplement 13 · standardAP
1997-02-06Manufacturing (CMC) · Supplement 12 · standardAP
1995-03-22Manufacturing (CMC) · Supplement 6 · standardAP
1995-02-02Manufacturing (CMC) · Supplement 9 · standardAP
1995-02-02Manufacturing (CMC) · Supplement 7 · standardAP
1995-02-02Manufacturing (CMC) · Supplement 8 · standardAP
1994-08-15Labeling · Supplement 10 · standardAP
1994-01-03Manufacturing (CMC) · Supplement 11 · standardAP
1993-07-06Manufacturing (CMC) · Supplement 5 · standardAP
1992-11-23Labeling · Supplement 4AP
1992-01-06Manufacturing (CMC) · Supplement 2 · standardAP
1991-07-25Labeling · Supplement 1AP
1989-11-22Type 3 - New Dosage Form · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →